Boehringer Ingelheim and Cue Biopharma, announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B...
Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into...
Cognizant announced it is working with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development. Leveraging...
Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents...
Plug and Play Tech Center, a global innovation platform, announced a new partnership with Boehringer Ingelheim (Canada) Ltd., a leading research-driven biopharmaceutical company. Boehringer-Ingelheim...
